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Abstract
Aim In addition to respiratory symptoms, COVID-19
can present with gastrointestinal complaints suggesting
possible faeco-oral transmission. The primary aim of this
review was to establish the incidence and timing of posi-
tive faecal samples for SARS-CoV-2 in patients with
COVID-19.
Methods A systematic literature review identified studies
describing COVID-19 patients tested for faecal virus.
Search terms for MEDLINE included ‘clinical’, ‘faeces’,
‘gastrointestinal secretions’, ‘stool’, ‘COVID-19’, ‘SARS-
CoV-2’ and ‘2019-nCoV’. Additional searches were done
in the American Journal of Gastroenterology, Gastroenterol-
ogy, Gut, Lancet Gastroenterology and Hepatology, the
World Health Organization Database, the Centre for Evi-
dence-Based Medicine, New England Journal of Medicine,
social media and the National Institute for Health and
Care Excellence, bioRxiv and medRxiv preprints. Data
were extracted concerning the type of test, number and
timing of positive samples, incidence of positive faecal tests
after negative nasopharyngeal swabs and evidence of viable
faecal virus or faeco-oral transmission of the virus.
Results Twenty-six relevant articles were identified.
Combining study results demonstrated that 53.9% of
those tested for faecal RNA were positive. The duration
of faecal viral shedding ranged from 1 to 33 days after a
negative nasopharyngeal swab with one result remaining
positive 47 days after onset of symptoms. There is
insufficient evidence to suggest that COVID-19 is
transmitted via faecally shed virus.
Conclusion There is a high rate of positive polymerase
chain reaction tests with persistence of SARS-CoV-2 in
faecal samples of patients with COVID-19. Further
research is needed to confirm if this virus is viable and
the degree of transmission through the faeco-oral route.
This may have important implications on isolation, rec-
ommended precautions and protective equipment for
interventional procedures involving the gastrointestinal
tract.
Keywords COVID-19, faeces, gastrointestinal, SARS-
CoV-2, viral shedding
Introduction
The rapid progression of the COVID-19 pandemic has
created significant challenges for the public as well as
healthcare professionals around the world. Knowledge
regarding virus incubation, transmission and shedding is
crucial for the reduction of new cases and protection of
healthcare professionals. Guidance regarding isolation
and protective equipment has changed as evidence has
increased and developed.
The high incidence of cough and fever in COVID-19
is well established [1]. Gastrointestinal symptoms are also
well documented suggesting a potential faeco-oral trans-
mission route [2]. Discharge guidelines for hospitals for
declaring a COVID-19 patient recovered in the UK are
largely based on time from either symptom onset or posi-
tive test depending on the severity of illness and the dis-
charge destination [3].The European Centre for Disease
Prevention and Control, on the other hand, has advo-
cated the need for continued self-isolation and hand
hygiene measures even 14 days post-discharge based on
prolonged viral shedding in faeces and respiratory sam-
ples [4]. This evidence may influence the recommended
duration of self-isolation, home sanitation practices dur-
ing isolation and after discharge and the use of protective
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equipment for procedures involving the gastrointestinal
tract. Evidence-based recommendations for specialities
such as gastroenterology, gastrointestinal endoscopy and
gastrointestinal surgery are required where there may be
an exposure risk to virus shed in faeces. Despite viral
RNA being detected in the air or other surface samples
like toilets, it is still unclear whether it is viable to trans-
mit infection through this route [5].
The primary aim of this review is to assess the inci-
dence and timing of positive faecal samples for SARS-
CoV-2 in relation to the clinical course of patients with
COVID-19.
Our secondary aims are to establish the incidence of
patients with positive faecal samples after negative respi-
ratory swabs and any evidence to suggest faecal virus
transmitted infection.
Method
Reports of cases or studies of COVID-19 patients with
evidence of the virus in faecal samples were systemati-
cally identified and full text articles were reviewed for
data extraction.
Literature search
A comprehensive search was undertaken as per the search
strategy outlined below for literature that included
SARS-CoV-2 virus testing of faeces. MEDLINE was
searched to find articles published until 3 April 2020.
The defined search terms were created after collaboration
between the authors experienced in gastroenterology,
colorectal surgery and systematic review. Search terms
reflected the aim to identify studies with evidence of fae-
cal COVID-19 and included ‘clinical’, ‘faeces’, ‘gastroin-
testinal secretions’, ‘stool’, ‘COVID-19’, ‘SARS-CoV-2’
and ‘2019-nCoV’. Additional manual searches to identify
the most recent evidence were performed in the Ameri-
can Journal of Gastroenterology, Gastroenterology, Gut,
the Lancet Gastroenterology and Hepatology, the World
Health Organization (WHO) Database, the Centre for
Evidence-Based Medicine, the New England Journal of
Medicine and the National Institute for Health and Care
Excellence. COVID-19 preprints published until 10 April
2020 on medRxiv and bioRxiv and an independent
search on social media (Twitter) by the authors (SS, SD)
added more articles. The search strategy used for social
media and a brief description of the WHO and other
databases are provided in Appendix S1.
Inclusion and exclusion criteria
Articles describing COVID-19 patients who had faecal
or stool specimens tested for the virus were included.
Considering the knowledge gaps existing for COVID-
19 all articles were considered regardless of the number,
age or gender of patients or the country of publication.
Animal-based studies or articles without an available full
text were excluded. Foreign language articles were con-
sidered but excluded unless the necessary language
expertise was available within the research group.
Study identification
Articles were sorted alphabetically by author name and
divided between two reviewers (SG and JP). Abstracts
were reviewed and classified by the same two authors
through the Rayyan Web Application [6] to identify
those for full text review. The same process was used
for full text articles and these data were managed
through EndNote (EndNote X9.3.1 license provided by
Cardiff University). Articles were then discussed
between the same reviewers to identify the final selec-
tion of full text articles. Any conflicts were solved by
the supervising author if necessary. Reference lists and
review articles were cross-referenced to identify any fur-
ther original studies. All articles were categorized and
described in a PRISMA flow chart.
Data extraction
The final data extraction was also carried by the two
reviewers (JP and SG) and managed through Microsoft
Excel files. The data parameters extracted from the
studies are shown in Table 1. The final data were veri-
fied by the two reviewers (JP and SG) with conflict res-
olution as described previously if necessary.
Results
MEDLINE searches identified 565 articles and 194
were found through other databases. An overview of
the selection process is shown in the PRISMA chart in
Table 1 Data parameters for extraction.
1. Study reference
2. Country of publication
3. Number and type of patients in the study
4. Type of sample taken (faecal sample, anal swab, RT-PCR,
culture)
5. Number of patients having faecal samples tested and
number of positive samples
6. Timing of positive faecal swab after symptom onset
7. Duration of positive faecal specimen after negative
nasopharyngeal swab
8. Any evidence for viable faecal virus or faeco-oral
transmission documented in the study
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Fig. 1. There were 26 articles [7–32] included in the
final analysis. An overview of the patient demographics
is summarized in Table 2.
Most studies were from China (n = 20) with two
from the USA and one each from Italy, Korea, Vietnam
and France. The number of participants recruited in the
studies ranged from 1 to 206 with ages ranging from
3 months to 87 years. Sample collection consisted of
faecal samples or anal or rectal swabs. Quantitative
reverse transcription polymerase chain reaction (RT-
PCR) was the test performed on all samples to detect
viral RNA.
The indication for faecal testing was not specified in
most studies. In some the test was done in
Records identified through WHO, CEBM, Lancet 
Gastro Hep, AJG, NEJM, GUT, Gastroenterology, 
NICE (n = 104); Cross referenced (n = 13); bioRxiv and 
medRxiv (n = 52); Social Media (25)
Records identified through Medline 
search
(n = 565)
Duplicates removed
(n = 59)
Records excluded
(n = 651)
Reasons: Animal based (2)
Foreign language (2)-Chinese and 
Spanish
Wrong study design (647)
Records screened
(n = 700)
Full text articles assessed for 
eligibility
(n = 49)  
Full text articles excluded with 
reasons:
Did not answer fecal shedding of 
virus
(n = 23)
Studies included in quantitative 
analysis
(n = 26)
Figure 1 PRISMA flow chart.
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asymptomatic patients for screening after contact with
an infected person or travel history to an infected area.
The predominant symptoms of presentation in the stud-
ies were persistent cough, fever and breathlessness with
fewer patients reporting diarrhoea or vomiting. All stud-
ies had information regarding our primary aim of
reporting faecal samples for the virus in those with
COVID-19. Of these, 16 [7,10,11,14–19,23,24,26–
30] provided information on the duration of these tests
after symptom onset and evidence of positive faecal
samples after symptom recovery, discharge from the
hospital or negative nasopharyngeal RT-PCR. The data
extraction is summarized in Tables 3 and 4 which are
divided based on the number of patients tested for fae-
cal RT-PCR in the study (≤ 10 and > 10 respectively)
and the detailed combined table is attached as supple-
mentary results (Table S1).
A total of 824 patients were included across the
studies and 540 were tested for faecal viral RNA [7–
32]. Positive faecal RT-PCR tests occurred in 291
(53.9%). The timing of the first positive sample was
available in 21 studies and varied from day 0 of
symptom onset to day 17. Late positive tests do not
necessarily equate to absence of the virus earlier in the
illness but may reflect the heterogeneity in testing pat-
terns amongst the studies. First stool samples were
often reported late after hospital admission [11] or even
after discharge [28] while some were analysed from day
1 of hospitalization or symptom onset
[19,20,27,29,32]. There is a similar discrepancy in fol-
low-up testing. Some tested until samples were found
to be negative [17] while others did not [18,29].
Of 199 patients who tested positive for faecal viral
RNA and who were followed up with stool testing, 125
(62.8%) showed persistent shedding of virus in the stool
samples after a negative nasopharyngeal swab while in
the individual studies it ranged from 23.3% to 100%.
The duration for faecal shedding of viral RNA after
clearance of respiratory samples ranged from 1 to
33 days and in one patient up to 47 days from symp-
tom onset [26].
None of the studies was designed to detect live virus
in the faeces except for the study by Wang et al. [25].
Of 153 stool specimens tested in this study, 44 were
Table 2 Overview of patient demographics from studies included in the review [7–32].
Reference Country Number of patients in study Type of patients Type of sample
Cai et al. [7] China 10 Children, 3–131 months Faeces
Chan et al. [8] China 6 Family cluster (10–66 years) Faeces
Chen et al. [9] China 1 Man, 34 years Faeces
Chen et al. [10] China 1 Woman, 25 years Faeces
Chen et al. [11] China 57 Unclear Anal swab
Han et al. [12] China 206 Adults Faeces
Holshue et al. [13] USA 1 Man, 35 years Faeces
Kim et al. [14] Korea 2 Adult: man and woman Faeces
Kujawski et al. [15] USA 12 Adults Faeces
Lescure et al. [16] France 5 Adults Faeces
Ling et al. [17] China 66 Adults Faeces
Lo et al. [18] China 10 9 adults, 1 child Faeces
Nicastri et al. [19] Italy 1 Adult, late 20s Faeces
Pan et al. [20] China 17 Laboratory samples Faeces
Peng et al. [21] China 9 Adults Anal swab
Song et al. [22] China 1 Middle aged woman Anal swab
Tan et al. [23] China 1 Man, 73 years Rectal swab
Tang et al. [24] China 1 Man, 10 years Faeces
Wang et al. [25] China 205 Adults and children, mean age 44 years Faeces
Wu et al. [26] China 74 Laboratory samples Faeces
Xiao et al. [27] China 73 Children and adults, 10 months to 78 years old Faeces
Xing et al. [28] China 3 Children, 1.5–6 years Faeces
Xu et al. [29] China 10 Children, 2 months to 15 years Rectal swab
Zhang et al. [30] China 23 Adults, median age 48 years Faeces
Zhang et al. [31] China 14 Adults, median age 41 years Faeces
Zhang et al. [32] China 15 Laboratory samples Anal swab
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PCR positive and, of four specimens cultured, live virus
was detected in two [25].
Discussion
This rapid review demonstrates a high incidence and
persistence of positive faecal RT-PCR tests for SARS-
CoV-2 after negative nasopharyngeal swabs in patients
with COVID-19. This may have important implications
regarding measures to prevent the spread of disease,
precautions recommended for the public and protective
equipment for health professionals performing interven-
tions involving the gastrointestinal tract.
A Chinese review performed by Tian et al. [33] sum-
marized evidence on the importance of identifying gas-
trointestinal symptoms in addition to the respiratory
symptoms of patients with COVID-19. Despite persis-
tent shedding of SARS-CoV-2 virus in faeces there
seems to be no correlation with the presence or severity
of gastrointestinal symptoms based on the limited data
available. Our review adds to this evidence from China
and describes the plausibility of faeco-oral transmission.
Despite this review demonstrating a high incidence
of positive tests for virus in the faeces, the absence of
evidence to confirm infectivity from this must be
emphasized. In order to adequately confirm this, good
quality evidence is required to demonstrate infectious
virus in faeces and its risk of transmitting disease
between individuals. These data may then enable the
development of reliable guidelines and recommenda-
tions. However, given the rapid development of the
pandemic, this will take time and reviews such as this
may help guide focused and valuable research questions
for the future. The findings of our review provide a syn-
opsis of the best available evidence regarding SARS-
CoV-2 in the faeces at the current time.
Evidence regarding other coronaviruses may be
helpful in this context. Similar patterns of virus
Table 3 Overview of data extracted from studies included in the review with ≤ 10 patients tested for faecal virus [7–10,13,14–
16,18,19,21–24,28,29]
Reference
Patients with positive
faecal RT-PCR
Timing of positive
faecal RT-PCR
(from symptom onset
unless stated otherwise)
Number of
patients with
positive faecal
RT-PCR
and negative
NP RT-PCR
Duration of persistent
positive faecal RT-PCR
after negative NP RT-PCR
Cai et al. [7] 6 tested, 5 positives (83.3%) First test at 3–13 days
Second test at 18–30 days
Positive in all patients
on both tests
5 out of 5 (100%) Ranged from 11 to 18 days
Chan et al. [8] 4 tested, 0 positive NA NA NA
Chen et al. [9] 1 tested, 0 positive NA NA NA
Chen et al. [10] 1 tested, 1 positive (100%) Day 11 1 out of 1 (100%) 1 day
Holshue et al. [13] 1 tested, 1 positive (100%) Day 7 Not available Not available
Kim et al. [14] 2 tested, 2 positives (100%) Ranged from day 8 to 17 0 out of 2 NA
Kujawski et al. [15] 10 tested, 7 positives (70%) Ranged from day 6 to 18 2 out of 7 (28.6%) Ranged from 4 to 6 days
Lescure et al. [16] 5 tested, 2 positives (40%) Ranged from day 2 to 13 1 out of 2 (50%) 3 days
Lo et al. [18] 10 tested, 10 positives (100%) Ranged from day 2 to 19 4 out of 10 (40%) Ranged from 2 to 10 days
Nicastri et al. [19] 1 tested, 1 positive (100%) Day 3 after admission 0 out of 1 NA
Peng et al. [21] 9 tested, 2 positives (22.2%) Patient 1: day 3
Patient 2: unknown
Not available Not available
Song et al. [22] 1 tested, 0 positive NA NA NA
Tan et al. [23] 1 tested, 1 positive (100%) Up to day 23 1 out of 1 (100%) 7 days
Tang et al. [24] 1 tested, 1 positive (100%) Ranged from day 17 to
25 after exposure
1 out of 1 (100%) 10 days
Xing et al. [28] 3 tested, 3 positives (100%) Patient 1 and 2: day 4
Patient 3: day 9
(after discharge)
3 out of 3 (100%) 8 and 20 days
Xu et al. [29] 10 tested, 8 positives (80%) Ranged from day 1 to 3 8 out of 8 (100%) Ranged from 3 to 21 days
NA, not applicable; NP, nasopharyngeal; RT-PCR, reverse transcription polymerase chain reaction.
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isolation from stool and faeco-oral transmission were
observed for other coronaviruses including SARS-
CoV-1 [34]. Bio-aerosol generation of viral particles
as a result of toilet flushing, the impact of disinfec-
tion on this [35,36] and the persistence of
coronaviruses on surfaces has been studied before
[37]. Other indirect evidence of microbial exposure
and contamination of the operator’s face during
endoscopy [38] and laboratory evidence of SARS-
CoV-2 infection of the gastrointestinal tract and
Table 4 Overview of data extracted from studies included in the review with > 10 patients tested for faecal virus [11,12,17,20,25–
27,30–32].
Reference
Patients with positive
faecal RT-PCR
Timing of positive faecal
RT-PCR (from symptom
onset unless stated otherwise)
Number of patients
with positive faecal
RT-PCR and
negative NP RT-PCR
Duration of persistent
positive faecal RT-PCR
after negative NP RT-PCR
Chen et al. [11] 28 tested, 11
positives (39.3%)
Only specify timings
in two patients
Patient 1: day 13
Patient 2: day 10
1 out of 2 (50%) 3 days
Han et al. [12] 22 tested, 12
positives (54.5%)
Not available Not available Not available
Ling et al. [17] 66 tested, 66
positives (100%)
Not available 43 out of 66 (65%) Duration to negative NP
sample ranged from
6 to 11 days
(median 9.5 days) vs
Duration to negative faecal
sample ranged from
9 to 16 days
(median 11 days)
NB: 11 patients still
had positive faecal RT-PCR at
31 days after admission to
convalescence
Pan et al. [20] 17 tested, 9
positives (53%)
Ranged from day 0 to 11 Not available Not available
Wang et al. [25] 153 tested, 44
positives (29%)
Not available Not available Not available
Wu et al. [26] 74 tested, 41
positives (55%)
Variable 32 out of 41 (78%) Faecal sample remained
positive for a mean
duration of 27.9 days (9.2 days
longer than positive respiratory
sample)
Patient 1: 33 days after
negative nasopharyngeal swab
Patient 2: 47 days from
symptom onset
Xiao et al. [27] 73 tested, 39
positives (53.4%)
Ranged from
day 1 to 12 days
17 out of 39 (23.3%) Not available
Zhang et al. [30] 12 tested, 10
positives (83.3%)
Day 4 6 out of 10 (60%) Median duration of
positive NP sample 10 days vs
median duration of positive
faecal sample 22 days
Zhang et al. [31] 14 tested, 5
positives (35.7%)
Ranged from day 4 to 10 Not available Not available
Zhang et al. [32] 15 tested, 4
positives (26.7%)
Ranged from day 0 to 5 Not available Not available
NA, not applicable; NP, nasopharyngeal; RT-PCR, reverse transcription polymerase chain reaction.
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mechanisms [39,40] add to the evidence for plausibil-
ity of transmission.
The risk to healthcare professionals from patient
exposure is well known, specifically in high aerosol gen-
erating procedures. Professional societies and investiga-
tor groups from countries with experience of managing
COVID-19 in the context of gastrointestinal interven-
tions [41,42] highlight the risk to individuals in endo-
scopy departments and the need for necessary
precautions including negative pressure rooms and per-
sonal protective equipment for both upper and lower
gastrointestinal procedures. This review supports the
importance of these measures given a high prevalence
and persistence of SARS-CoV-2 virus in faeces. Isolation
of live virus is confirmed only by one study [25] and
the proportion of cases that might be transmitted by
this route is unclear due to the heterogeneity in case
selection and lack of standardization of study designs
and protocols. Environments such as care homes may
be particularly vulnerable to transmission of infection by
this route and recommendations must take into account
this evidence to ensure the protection of health and
social care providers and the general public in the
meantime. Application of these data to the population
may be helpful in guiding the recommendations for iso-
lation periods to reduce transmission rates.
Limitations
Despite finding a high incidence of positive faecal sam-
ples for SARS-CoV-2 in the included studies, our
review cannot confirm the true population prevalence of
positive faecal samples or the rate of false negatives.
This is due to the significant variability in study design
which is an inherent problem with COVID-19 research
at present. This heterogeneity was not formally assessed
due to it being a rapid review but can be clearly identi-
fied on inspection of the study designs and outcomes.
The variability in patient numbers and characteristics,
sample timing, sample nature (faecal samples vs anal or
faecal swabs) and follow-up testing should be consid-
ered when interpreting the reliability of the results. If
other studies confirm viable virus in stool, then meth-
ods of culture also need to be described and standard-
ized for comparison and replication in other
populations. The majority of the included studies are
small, heterogeneous, retrospective and often did not
assess viral shedding in the faeces as their primary aim.
At present, however, this is the only evidence available.
There were two foreign language articles excluded due
to lack of translation resources. The preprints are not
peer reviewed and therefore should be treated with
caution.
Conclusion
The duration of viral shedding in the faeces is mostly
reported from 1 to 33 days after a negative nasopharyn-
geal swab but can continue for up to 47 days after
onset of symptoms in patients with COVID-19. These
positive samples can occur after negative nasopharyngeal
swabs or resolution of patient symptoms. Isolation of
live virus in stool specimens of two cases in a single
study supports the possibility of faeco-oral transmission.
Further research is needed to prove whether this viral
shedding in stool results in a significant proportion of
case transmissions in the community as well as within
care institutions and secondary care. Until further evi-
dence is generated appropriate precautions should be
recommended for the protection of healthcare workers
and patients.
Implications for the public
1 In addition to strict adherence to hand washing rec-
ommendations, home toilet sanitary and disinfection
precautions should be taken in the case of isolation
or contact with a symptomatic COVID-19 case with
or without gastrointestinal symptoms. This statement
is based on limited evidence of possible viable faecal
virus excretion.
2 These precautions may need to continue for longer
than the period of symptoms and the current recom-
mendations for isolation after symptoms cease. This
statement is based on limited evidence of the dura-
tion after the onset of symptoms that an RT-PCR
stool test might still be positive.
Implications for healthcare professionals
1 Professional bodies’ recommendations on protective
equipment, endoscopic and surgical procedures for
COVID-19 patients should be followed [43–46].
2 The possibility of faeco-oral transmission should be
borne in mind with implications for endoscopy and
theatre disinfection of surfaces in between proce-
dures.
3 Ward areas for COVID-19 patients and care homes
or similar institutions may need to consider the
implications for infection control and disinfection
in the light of the possibility of faeco-oral transmis-
sion.
4 Screening processes for patients due to undergo
investigational or interventional procedures may need
to consider including gastrointestinal symptoms and
stool testing in future pre-procedure questionnaires.
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5 Healthcare teams managing patients with gastroin-
testinal symptoms may need to consider the possibil-
ity of COVID-19 coexisting with or worsening
symptoms of underlying conditions such as inflam-
matory bowel disease [47].
Recommendations for further research
1 Future studies on viral shedding and infectivity of
SARS-CoV-2 should consider standardization of
sampling methods in terms of the timing and the
type of sample collection, with appropriate precau-
tions for laboratory staff handling these samples until
the situation is clearer.
2 Study designs may wish to consider repeat and paral-
lel sampling with nasopharyngeal swabs at defined
time points. This may be correlated with symptoms
and serology to clarify the effect of neutralizing anti-
bodies and viable virus excretion in the stool.
3 Study designs may benefit from testing stool samples
from comparable groups. This could include symp-
tomatic, asymptomatic or recovered individuals in
and out of family clusters and with or without gas-
trointestinal symptoms. This may improve our under-
standing of clinical and public health implications
and potential targets for intervention in these set-
tings.
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